MORE medicines used for the treatment of cancer, diabetes and mental illness have been added to the list of value-added tax (VAT)-exempt drugs, according to the Bureau of Internal Revenue (BIR).

The U.S. Food and Drug Administration on Thursday found that there was no longer a shortage of Eli Lilly's blockbuster weight ...

Lawsuits filed in New Jersey are part of hundreds of complaints against UnitedHealthcare, PBMs, and pharmaceutical giants ...

As of today, three other GLP-1 receptor agonists remain on the FDA's shortage list: semaglutide (Ozempic, Wegovy), ...

Despite this escalating demand for popular GLP-1 drugs, the prices for some of these products are actually dropping. Dr.

Novo Nordisk made a submission to the U.S. Food and Drug Administration (FDA) nominating Novo Nordisk’s semaglutide ...

It’s likely to still be there at the end of the year, but by the time the final sales figures for 2024 are tallied up, Novo ...

But weight loss alone does not explain the drugs’ benefits. Both Holst and Sattar pointed to a discontinued GLP-1 drug once ...

Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart disease and Alzheimer’s ...

They are currently approved for treating diabetes, obesity and those with a history of cardiovascular disease in people who ...

Weight loss drugs, compounding, vitamin D, and AI all piqued readers’ interest — and sometimes, ire — this past year.

We recently compiled a list of the 12 Best Weight Loss Stocks to Buy According to Hedge Funds. In this article, we are going ...